Anti-Human CD64 (FCGR1) – Purified in vivo PLATINUM™ Functional Grade

The clone 10.1 is typically used to target CD64 (FcγRI) in human cells, which is involved in innate immunity. However, in the context of mice, it is primarily utilized to study human immune responses in humanized mouse models. While the clone 10.1 is not directly used in mice since it targets human CD64, humanized mouse models are designed to express human immune components, allowing researchers to study human immune responses in vivo. Common applications include:

1. Immunological Research: Humanized mouse models with the clone 10.1 can be used to study monocyte and macrophage functions, as well as to phenotype immune cells in both research and clinical samples. However, these models would require modifications to express human CD64 or incorporate human immune cells.

2. Pharmacological Studies: The development of mouse models that express human Fcγ receptors (like the one described in PNAS) allows for the testing of human monoclonal antibodies in a more relevant in vivo setting. Although clone 10.1 is not used in these mice directly, the principle of using humanized models applies.

3. Cancer and Disease Models: Humanized mouse models can be used to study cancer treatments, including the use of antibodies that target specific human antigens, thereby enabling more accurate preclinical testing of therapies.

For specific applications of clone 10.1 itself, it is primarily used in flow cytometry and other immunological studies in human or humanized contexts rather than in standard mouse models. However, the concept of using humanized models provides a framework for studying human immune interactions in mice.

In summary, while clone 10.1 is not directly applied in mice, it highlights the importance of using humanized models for studying human immune responses in vivo.

Clone 10.1 (anti-CD64) is most commonly used in conjunction with antibodies against other immune cell markers to analyze and phenotype monocyte and macrophage populations in immunological studies.

Key antibodies and proteins frequently used with 10.1 include:

• CD14: A marker for monocytes/macrophages, often used to distinguish these cells from other leukocytes.
• CD16: Helps further characterize monocyte subsets (classical, intermediate, non-classical) and NK cells.
• HLA-DR: Indicates MHC class II expression, useful for assessing activation states of myeloid cells.
• CD45: A pan-leukocyte marker for identifying total leukocyte populations.
• CD11b: An integrin associated with monocytes, macrophages, granulocytes, and NK cells, helpful for myeloid cell identification.
• CD11c: Expressed on monocytes, macrophages, and dendritic cells, included for finer myeloid subset analysis.

These antibodies are typically used in multiparameter flow cytometry panels or immunophenotyping assays to comprehensively define myeloid cell populations, distinguish cell subsets, and assess activation or differentiation states.

Other applications for 10.1 in the literature, occasionally combined with additional proteins or antibodies, include:

• Blocking of human IgG3 and murine IgG2a binding to FcγRI, particularly in Fc receptor function studies.
• Immunohistochemistry on tissue sections, where macrophage and monocyte markers may be co-stained to study tissue localization.

In summary, 10.1 is almost always used alongside other lineage or activation markers—especially CD14, CD16, HLA-DR, CD45, CD11b, and CD11c—to provide a comprehensive analysis of human myeloid cell populations in research contexts.

Clone 10.1 is often mentioned in scientific literature in relation to its use as a monoclonal antibody recognizing human CD64 (FcγRI), a receptor expressed on monocytes/macrophages, dendritic cells, and activated granulocytes. While specific citations related to clone 10.1's findings are not detailed in the provided search results, here are key points about CD64 and the implications of clone 10.1:

1. Recognition of CD64: Clone 10.1 specifically binds to the extracellular epitope of CD64, which is crucial for studying immune responses and cell interactions involving IgG antibodies.

2. Applications in Immunology: The antibody is commonly used to identify and characterize monocyte and macrophage populations, aiding in understanding their roles in immune diseases and responses.

3. Research and Diagnostic Use: Clone 10.1 is used in research settings for its specificity and affinity towards CD64, but it is not intended for diagnostic procedures.

Given the lack of detailed citations about specific findings from clone 10.1 in the provided results, these points summarize the general application and significance of clone 10.1 in scientific research. For specific findings or studies, additional literature review would be necessary.

While the specific dosing regimen for clone 10.1 (Anti-Human CD64) in different mouse models is not detailed in the search results, dosing regimens for antibodies like clone 10.1 can vary significantly based on the mouse model used, the experimental objective, and the type of antibody. Typically, dosing regimens for antibodies in mouse models are determined by factors such as the target antigen, the desired immune response, and the specific application of the antibody.

For general guidance, dosing regimens for antibodies in mouse models often involve intraperitoneal or intravenous injections, with dosages ranging from 100 to 500 μg per mouse, depending on the antibody's target and the study's objectives. The frequency of dosing can vary from every 2-3 days to once a week, also depending on the study's requirements.

Since clone 10.1 targets human CD64, it might be used in models where human immune cells are engrafted, such as in humanized mouse models used for studying human immune responses. In these cases, the dosing regimen would need to be tailored specifically to the model's characteristics and the experimental goals.

To determine the optimal dosing regimen for clone 10.1 in a specific mouse model, it would be necessary to consult specific studies using this antibody or to conduct pilot studies to establish the most effective dosing strategy.